Asia Deal Watch: Daiichi Sankyo Obtains Brazilian Rights To Mitsubishi Tanabe’s ALS Drug
Daiichi Sankyo also gets right of first negotiation for edaravone, approved in the US and Japan, in other Central and South American markets. Astellas advances its “Rx+” strategy in partnership with iota Biosciences.
You may also be interested in...
The JV to be called JAGUAHR Therapeutics will focus on the AhR pathway. Simcere acquires Chinese rights to JW’s gout candidate.
Stempeutics explores stem cell therapy in India for Crohn’s disease-related perianal fistulae while considering entry into other Asian markets.
Biocon has joined the march of Indian firms into China, tying up with Chinese firm CMS to sell three generic formulations in the world’s second-largest drug market.